Slowing Axial Elongation in Pediatric Myopia Using C.A.R.E. Technology
Key facts
- Who runs it
- Benha University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 100 people enrolled
- Started
- 15 Jan 2024
- Ended
- 15 Mar 2025
- Type of study
- Interventional
- Treatments tested
- Cylindrical Annular Refractive Element (C.A.R.E.) Spectacle Lenses
- Record updated
- 12 March 2026
Who can take part
- Age
- 6 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Children aged 6-12 years at enrollment
- Spherical equivalent refractive error between -0.75 and -6.00 diopters
- Astigmatism ≤1.50 diopters
- Best-corrected visual acuity of 0.1 logMAR or better
- Ability to comply with full-time spectacle wear
- Informed consent obtained from parent or legal guardian
Who cannot take part
- Previous myopia control treatment (e.g., atropine therapy, orthokeratology)
- History of ocular surgery
- Systemic disease affecting vision
- Amblyopia or strabismus
- Keratoconus or other corneal pathology
- Poor compliance with spectacle wear
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This prospective interventional study evaluates the effectiveness of Cylindrical Annular Refractive Element (C.A.R.E.) spectacle lenses in slowing axial elongation and myopia progression in children aged 6-12 years. A total of 100 participants with myopia ranging from -0.75 to -6.00 diopters were enrolled and prescribed C.A.R.E. spectacle lenses for full-time wear over a 12-month period. Clinical examinations are conducted at baseline, 6 months, and 12 months and include measurements of axial length, cycloplegic refraction, and visual acuity.
Read full original descriptionShow less
The primary outcome measure is the change in axial length over the 12-month study period. Secondary outcomes include changes in spherical equivalent refractive error, visual acuity, and safety outcomes related to spectacle lens wear.
The group in the trial
- C.A.R.E. Spectacle Lenses - Pediatric Myopia ControlTreatment being tested
All participants received Cylindrical Annular Refractive Element (C.A.R.E.) spectacle lenses. The lenses feature a central optical zone for distance correction surrounded by concentric annular cylindrical elements designed to modify peripheral retinal defocus and slow axial elongation. Participants were instructed to wear the spectacles full-time during waking hours for 12 months. Follow-up examinations occurred at baseline, 6 months, and 12 months to assess axial length, refractive error, visual acuity, and safety.
Treatment: Cylindrical Annular Refractive Element (C.A.R.E.) Spectacle Lenses
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Slowing Axial Elongation in Pediatric Myopia: One-Year Clinical Outcomes of Cylindrical Annular Refractive Elements (C.A.R.E.) Technology
- Record updated
- 12 March 2026